340B Program
Management.

The 340B Drug Pricing Program is a federal program that requires drug manufacturers to provide outpatient drugs at significantly reduced prices to eligible healthcare organizations - primarily Federally Qualified Health Centers (FQHCs), Ryan White clinics, Disproportionate Share Hospitals, and other safety-net providers. The program is administered by the Health Resources and Services Administration (HRSA).

Any HRSA-registered covered entity can benefit from 340B program management, including Federally Qualified Health Centers, health centers, Ryan White HIV/AIDS clinics, tuberculosis clinics, black lung clinics, hemophilia treatment centers, and specific hospital types such as Disproportionate Share Hospitals, Critical Access Hospitals, cancer centers, and Rural Referral Centers.

We integrate directly with your EMR and claims systems to analyze each patient encounter against HRSA's 'patient definition' criteria - confirming the provider was employed or contracted by the covered entity, the service was within the scope of a qualifying grant or contract, and documentation exists in the covered entity's records. Our algorithms continuously tune against your specific clinical workflow to maximize capture without risking compliance.

HRSA conducts approximately 200 audits per year. Common findings include diversion (dispensing 340B drugs to ineligible patients), duplicate discounts (receiving both 340B and Medicaid rebates on the same drug), and inadequate documentation. Penalties range from repayment of manufacturer discounts to removal from the program. Remy's compliance-first approach includes quarterly self-audits and full audit-defense support.

Covered entities without in-house pharmacies can contract with external retail or specialty pharmacies to dispense 340B drugs on their behalf. These arrangements require formal written agreements, split-billing software, and careful reconciliation to prevent duplicate discounts. Remy manages the full lifecycle - from pharmacy selection and contracting through monthly reconciliation and revenue recovery.

For an established covered entity, our typical implementation takes 8 weeks: 3 weeks of diagnostic work (capture rate analysis, compliance review, benchmarking) followed by 5 weeks of build-out (eligibility engine configuration, contract pharmacy activation, reporting infrastructure). New 340B registrants will have a longer runway due to HRSA registration timelines.

Savings vary based on patient volume, prescribing patterns, and existing program maturity. Our covered entity partners typically see a 40%+ increase in captured savings in year one versus their prior administration, with continued growth in subsequent years as contract pharmacy networks expand and capture rates stabilize. A diagnostic assessment is the best way to benchmark your specific opportunity.

We offer both fixed-fee and savings-share structures depending on program size and complexity. Fixed-fee arrangements work well for established programs with predictable volume; savings-share arrangements align our incentives with growth for programs earlier in their maturity. We'll discuss both options during your discovery call and recommend the structure that fits your situation.